Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM CD versus DILACOR XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM CD versus DILACOR XR.
CARDIZEM CD vs DILACOR XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in dilation of coronary arteries and peripheral arterioles, and decreased myocardial contractility and conduction velocity.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Hypertension: 180-360 mg once daily orally. Angina: 120-360 mg once daily orally. Maximum dose: 480 mg/day.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (single dose), prolonged to 10-15 hours with multiple dosing or in elderly/hepatic impairment. Clinical context: Therapeutic steady-state achieved in 2-4 days.
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Renal: ~2-4% (unchanged), Hepatic metabolism to multiple metabolites; ~65% renal (metabolites), ~35% fecal/biliary. Total clearance: 5-7 mL/kg/min.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker